BLUFFDALE, Utah, January 15, 2024 — Med 7, LLC (www.med7cbd.com) announces the recent granting of a US patent for Hempzorb81™, marking a significant milestone in the field of inflammation management. This groundbreaking patent highlights Med 7® as the first Full Spectrum CBD product to receive such recognition for its efficacy in addressing inflammation-related conditions.
The comprehensive data within the patent underscores the transformative impact of Med 7® on inflammatory markers, particularly in reducing circulating levels of key indicators such as tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6). Impressively, regular consumption has been shown to decrease these inflammatory markers by as much as 25 to 50% or more. Additionally, markers signaling the presence of ongoing inflammation, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), have demonstrated reductions of up to 10 to 25% or more. The patent focuses specifically on treating patients with COVID-19 (SARS-CoV-2) with Med 7®, a full-spectrum hemp product made with Purzorb® technology, now trademarked as Hempzorb81™.
“We understand the pivotal role that inflammation plays in various diseases and the aging process. The ability of Med 7 to naturally and safely mitigate inflammation without the associated risks of serious side effects positions it as a revolutionary solution in the medical landscape,” said Matt Smith, CEO of Med 7.
“We believe that the granting of this US patent for Med 7 is a testament to our shared dedication to advancing health and well-being and offering cutting-edge, non-pharmaceutical options.”
About Med 7
Med 7® is a technology-driven company that markets and distributes health and wellness products to medical professionals. Hempzorb81™ is a full spectrum hemp product made with Purzorb® technology, which mimics the body’s natural process of absorption by converting oil-based nutrients into water-soluble products. Hempzorb81™ is patent pending for other human health conditions.
For more information: Contact Med7, LLC: 801-577-4223, public.relations@med7usa.com, www.med7cbd.com
To view the complete patent: 11826320 (uspto.gov)
